SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME
The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing...
Saved in:
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French Korean |
Published |
29.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient.
La présente invention concerne : un composé dérivé de thiazolidinedione substitué ayant une nouvelle structure agissant en tant qu'inhibiteur de protéine-1 de liaison à un élément régulateur de stérol (SREBP1), un hydrate de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci ; et une composition pharmaceutique pour prévenir ou traiter le cancer, le comprenant en tant que principe actif.
본 발명은 SREBP1(sterol regulatory element-binding protein-1) 저해제로 작용하는 신규 구조의 치환된 티아졸리딘디온 유도체 화합물, 이의 수화물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 이를 포함하는 암의 예방 또는 치료용 약학적 조성물에 관한 것이다. |
---|---|
Bibliography: | Application Number: WO2022KR20728 |